Development and caracterization, bench scale, pegylated liposomal formulation containing the anticancer drug doxorubicin

• Grant number: 16/15120-0
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: May 01, 2017
• End date: March 31, 2018
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Angelica Fernandez Silva
• Grantee: Angelica Fernandez Silva
• Principal investigators: Alessandra Franco Novelli
• Associated scholarship(s): 17/10754-3 - Development and caracterization, bench scale, pegylated liposomal formulation containing the anticancer drug doxorubicin, BP.PIPE

Abstract

Develop, bench scale, pegylated liposomal formulation containing the anticancer drug doxorubicin. Liposomes will be produced with experimental design and physico- chemically characterized with respect to the number of lamellae, size, stability, encapsulation efficiency and release profile. The results will compare with reference drug Caelyx®, manufactured by Janssen-Cilag. It will make studies scheduling of manufacturing process of formulating lipossomada bench to industrial scale, with all the risk mapping, calculations of scaling -up and determination of control methods in process and finished product. (AU)